Ask HopeStage to review this study with me
Leave your email and HopeStage can help you better understand this study.
Study reference: NCT07384312. HopeStage can help you review the study, but cannot decide medical eligibility.
CompletedNCT07384312
Study on the Antidepressant Effects and Mechanism of Action of Cang-ai Volatile Oil Based on Near-Infrared Functional Brain Imaging and the NT-Trk Signalling Pathway
This study is completed in China. It focuses on Depression Disorder.
DepressionOtherFrom 18 Years to 26 Years
Key information made simple
This study exists to explore whether brain scans or other body measurements could improve care and understanding. Researchers are trying to understand what brain scans or other body measurements can reveal about signals in the brain or body that may guide care later on. For people living with Depression, the gap between what sounds good on paper and what works in daily life is often important. If the findings are useful, they could help future care become more targeted, practical, and easier to trust. Taking part helps build the evidence that can improve understanding and care for others over time.
Your next step
The official record suggests in-person participation through a university, with sites including Yunnan University of Chinese Medicine in Kunming. Participation appears to involve guided sessions or support activities with check-ins on how they fit into daily life. The main fit is usually matching the main diagnosis. The official record does not list a formal phase, which usually means this is focused more on feasibility, delivery, or support than a standard drug-development stage.
Questions to ask before joining
- What are the exact eligibility criteria, and what could exclude someone?
- How many visits, assessments, or follow-ups are expected, and over what period?
- What risks, side effects, practical burdens, or alternatives should be understood first?
- Who should be contacted to confirm locations, timing, compensation, and next steps?
Things to check before joining
- Sponsor
- Dongdong Qin
- Sponsor type
- Unknown or unclear
- Main activity
- medication or study treatment
- Intervention
- Not available
- Time commitment
- long follow-up or multiple visits
- Study phase
- Not available
- Enrollment
- Not available
- Recruitment status
- Completed
- Source
- Official registry link
Key study information
- Official title
- Study on the Antidepressant Effects and Mechanism of Action of Cang-ai Volatile Oil Based on Near-Infrared Functional Brain Imaging and the NT-Trk Signalling Pathway
- Condition
- Depression Disorder
- Study status
- Completed
- Sponsor / lead affiliation
- Dongdong Qin
- Location / country
- China
- Registry
- ClinicalTrials.gov
- External trial ID
- NCT07384312
Why this study may matter
This study may matter because it adds public evidence around depression. HopeStage presents it as a starting point for understanding the study, checking the official source, and preparing questions with a care team.
For you
Taking part may help improve understanding of your condition.
It requires regular follow-up, often through questionnaires or interviews.
Requires travel, with in-person participation in China.
Registry reference
This page links back to the public source record so people can verify details directly with the registry and research team.
If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.
- Official title
- Study on the Antidepressant Effects and Mechanism of Action of Cang-ai Volatile Oil Based on Near-Infrared Functional Brain Imaging and the NT-Trk Signalling Pathway
- Source
- ClinicalTrials.gov
- Official registry link
- Open official registry
- External trial ID
- NCT07384312
Not medical advice
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
Questions about this study
What is Study on the Antidepressant Effects and Mechanism of Action of Cang-ai Volatile Oil Based on Near-Infrared Functional Brain Imaging and the NT-Trk Signalling Pathway?
This study is exploring medication or study treatment for people with depression. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed.
Who is behind this study, and what type of sponsor is it?
This study is sponsored by Dongdong Qin. We could not clearly classify the sponsor type from the available data. Check the official source record to verify who is responsible for the study.
What does participation involve, what phase is it, and what should I ask about safety?
This study may involve medication or study treatment, study visits, and assessments. The time commitment is long follow-up or multiple visits. The study phase is not available in HopeStage data. Check the official source record to see whether a phase is listed. Enrollment is not available in HopeStage data. HopeStage cannot say whether a study is safe or right for you. Before joining, ask the research team about possible risks, time commitment, visits, side effects, compensation, safety monitoring, and whether participation may affect your current care.
Where can I verify the study details?
Use the official source record linked on this page to check the full study description, recruitment status, eligibility criteria, locations, sponsor information, phase, enrollment, contact details, and any listed risks or requirements.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit me